In clinical trials of B-RAF–inhibitor monotherapy for cancer, investigators reported an unexpectedly common skin eruption with biopsy features diagnostic of GD (15, 16); subsequent analysis indicated GD was seen in 42.9% and 38.9% of patients treated with dabrafenib or vemurafenib, respectively (24). Here, BRAF is linked to cancer.